The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.

Ehlers, Lars H; Lamotte, Mark; Ramos, Mafalda C; Sandgaard, Susanne; Holmgaard, Pia; Kristensen, Malene M; Ejskjaer, Niels

Ehlers, Lars H; Lamotte, Mark; Ramos, Mafalda C; Sandgaard, Susanne; Holmgaard, Pia; Kristensen, Malene M; Ejskjaer, Niels.

Afiliación

Ehlers LH; Department of Clinical Medicine, Aalborg University, Ålborg, Denmark.
Lamotte M; IQVIA Global IQVIA, Da Vincilaan 7, 1930, Zaventem, Belgium. mark.lamotte@iqvia.com.
Ramos MC; IQVIA Global HEOR, Porto Salvo, Portugal.
Sandgaard S; Boehringer Ingelheim Denmark A/S, Copenhagen, Denmark.
Holmgaard P; Boehringer Ingelheim Denmark A/S, Copenhagen, Denmark.
Kristensen MM; Boehringer Ingelheim Denmark A/S, Copenhagen, Denmark.
Ejskjaer N; Department of Clinical Medicine, Aalborg University, Ålborg, Denmark.

Diabetes Ther ; 13(3): 489-503, 2022 Mar.

Article en En | MEDLINE | ID: mdl-35187628

Palabras clave

Cost-effectiveness; Costs and cost analysis; Denmark; Empagliflozin; GLP-1 receptor agonist; IQVIA Core Diabetes Model; SC semaglutide; SGLT-2 inhibitors; Treatment intensification; Type 2 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Diabetes Ther Año: 2022 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google